Literature DB >> 20466332

Adiponectin gene SNP276 variants and central obesity confer risks for hyperglycemia in indigenous Taiwanese.

Meng-Chuan Huang1, Tsu-Nai Wang, King-Teh Lee, Yu-Ju Wu, Hung-Pin Tu, Chih-Shan Liu, Hung-Che Chiang, Ying-Chin Ko.   

Abstract

This cross-sectional study analyzed the effects of two single nucleotide polymorphisms (SNP) of the adiponectin gene, SNP45 and SNP276, on hyperglycemia in indigenous Taiwanese, and whether central obesity modulates the effects of these SNPs. Overall, 550 indigenous Taiwanese were recruited for this cross-sectional study. The subjects were categorized into a hyperglycemic group if fasting plasma glucose was > 126 mg/dL (n = 88) or the control group if fasting plasma glucose was < 100 mg/dL (n = 462). The SNP276 TT homozygote carried greater hyperglycemia risk than SNP276 GG [odds ratio (OR) = 2.67, 95% confidence interval (CI) = 1.05-6.78], but not heterozygote (OR = 1.54, 95% CI = 0.95-2.50). SNP45 T > G was not associated with hyperglycemia risk. In multivariate-adjusted modeling, we found a significant relationship between SNP276 T carriers (GT + TT) (OR = 2.06, 95% CI = 1.10-3.88) and central obesity (OR = 4.50, 95% CI = 1.91-10.61) with hyperglycemia. Compared with non-central-obese carriers of SNP276 GG, non-central-obese SNP276 T carriers, and central obese subjects with SNP276 GG and SNP276 T carriers had 5.50, 8.31 and 13.76-fold, respectively, higher risks for hyperglycemia; obese carriers of the T-containing variants experienced a combined risk for hyperglycemia. Furthermore, the hyperglycemic risks were more pronounced in leaner (non-central-obese) individuals carrying the T variant than the central-obese individuals. The adiponectin SNP276 T variant and central obesity had independent and additive effects on hyperglycemia risks. These findings may provide valuable information regarding preventive strategies that might be useful to prevent or treat diabetes and its related complications. Copyright (c) 2010 Elsevier. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466332     DOI: 10.1016/S1607-551X(10)70033-4

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  5 in total

1.  276G>T Polymorphism of the ADIPOQ Gene Influences Plasma Adiponectin in Type 2 Diabetes Patients but Is Not Predictive for Presence of Type 2 Diabetes in a Caucasian Cohort from Romania.

Authors:  Ina Maria Kacso; Marius Florin Farcas; Ioan Victor Pop; Cosmina Ioana Bondor; Alina Ramona Potra; Diana Moldovan; Crina Rusu; Cristina Nita; Caprioara Mirela Gherman; Nicolae Dumitru Hancu
Journal:  Maedica (Buchar)       Date:  2012-12

2.  Amerindians show association to obesity with adiponectin gene SNP45 and SNP276: population genetics of a food intake control and "thrifty" gene.

Authors:  Antonio Arnaiz-Villena; Mercedes Fernández-Honrado; Diego Rey; Mercedes Enríquez-de-Salamanca; Sedeka Abd-El-Fatah-Khalil; Ignacio Arribas; Carmen Coca; Manuel Algora; Cristina Areces
Journal:  Mol Biol Rep       Date:  2012-10-30       Impact factor: 2.316

3.  Variations in Adipokine Genes AdipoQ, Lep, and LepR are Associated with Risk for Obesity-Related Metabolic Disease: The Modulatory Role of Gene-Nutrient Interactions.

Authors:  Jennifer Emily Enns; Carla G Taylor; Peter Zahradka
Journal:  J Obes       Date:  2011-04-19

4.  Single Nucleotide Polymorphism at +276 G>T of the Adiponectin Gene and Plasma Adiponectin Level in Myanmar Type 2 Diabetic Patients.

Authors:  Khin Thin Yu; Kyu Kyu Maung; Aye Thida; Thein Myint
Journal:  J ASEAN Fed Endocr Soc       Date:  2018-11-27

5.  ADIPOQ polymorphisms are associated with changes in obesity-related traits in response to aerobic training programme in women.

Authors:  Agata Leońska-Duniec; Anna Grzywacz; Zbigniew Jastrzębski; Aleksandra Jażdżewska; Ewelina Lulińska-Kuklik; Waldemar Moska; Katarzyna Leźnicka; Krzysztof Ficek; Agata Rzeszutko; Marcin Dornowski; Paweł Cięszczyk
Journal:  Biol Sport       Date:  2017-12-30       Impact factor: 2.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.